Moaaz Baghal, MD
Cardiovascular Disease · Toledo, OHNPI 1679032445
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,847 of the $5,561 with a category attached, or 69.2%. It is spread thinly across 29 manufacturers, the largest accounting for just 23.2%. 2025 is the largest year on record at $1,874, 6.5 times the $289 reported in 2022.
Across 94 payments — averaging $59.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$1K
- Medtronic$1K
- Shockwave Medical, Inc$726
- Stryker$367
- Atricure, Inc.$245
- Kestra Medical Technology Services, Inc.$230
- plus $2K from 23 others
What the payments were for
- Travel & lodging$1,54928%
- Food & beverage$3,84769%
- Education$1643%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 11 | $1,291 |
| Medtronic | 13 | $1,169 |
| Shockwave Medical, Inc | 12 | $726 |
| Stryker | 4 | $367 |
| Atricure, Inc. | 7 | $245 |
| Kestra Medical Technology Services, Inc. | 2 | $230 |
| Novo Nordisk | 2 | $211 |
| Novartis | 5 | $199 |
| Boston Scientific | 2 | $167 |
| Teleflex LLC | 5 | $164 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $106 |
| Actelion Pharmaceuticals US, Inc. | 1 | $99 |
| AstraZeneca | 2 | $93 |
| Merck | 1 | $67 |
| Alnylam Pharmaceuticals Inc. | 3 | $60 |
| Surmodics, Inc. | 1 | $47 |
| Cardiva Medical, Inc. | 2 | $40 |
| Imperative Care, Inc | 1 | $40 |
| Terumo Medical Corporation | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Scpharmaceuticals Inc. | 1 | $29 |
| Pfizer | 2 | $26 |
| Johnson & Johnson | 1 | $19 |
| Amgen | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Getinge USA Sales, LLC | 1 | $16 |
| Cordis US CORP. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,561 in reported general payments places this provider in the 75th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Toledo
- Rajendra KattarToledo$37K
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.